Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX3-71 in healthy volunteers
NCT04442945Phase 1Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Jul 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD), frontotemporal dementia (FTD) and schizophrenia comparing ANAVEX3-71 Oral with Placebo (2 arms). Primary endpoints: Number of participants with treatment-related adverse events and Dose Limiting Adverse Events (DLAEs) at 30 days, Pharmacokinetics (PK) of ANAVEX3-71 at 30 days and 2 more. Started Jul 2020; status: completed.
02
Drugs
anavex 3-71
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)schizophrenia
Beyond the preview
Go deeper on NCT04442945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442945.